



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T: 91 80 2808 2808
F: 91 80 2852 3423

CIN: L24234KA1978PLC003417

www.biocon.com

BIO/SECL/AJ/2023-24/98

October 09, 2023

To, The Secretary BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Secretary National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code – 532523	Scrip Symbol - Biocon

Subject: Intimation for the Board Meeting and Conference Call for Analysts and Investors

Dear Sir/Madam,

Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Friday, November 10, 2023, inter alia, to approve and take on record the un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2023, amongst other routine matters.

The trading window for dealing in securities of the Company for all insiders, as defined under the Code of Conduct for Prevention of Insider Trading ('the Code') of the Company, has been closed from Sunday, October 01, 2023 to Sunday, November 12, 2023 (both days inclusive) in compliance with the provisions of the Code of the Company read with SEBI (Prohibition of Insider Trading) Regulations, 2015. Accordingly, the trading window will be opened from Monday, November 13, 2023.

The Company will organize an Earnings Conference Call for analysts/investors on Friday, November 10, 2023. The details of the same is enclosed herewith.

The above-mentioned information will also be available on website of the Company at www.biocon.com.

Request you to take the above intimation on record.

Thanking You,

For **Biocon Limited**

Mayank Verma
Company Secretary and Compliance Officer
Membership No.: ACS 18776



20th K.M. Hosur Road, Electronics City, Bangalore 560 100

Bangalore, 9th October, 2023

Biocon's Q2 FY 2024 Results Conference Call

At 6:30 pm IST on 10th November 2023

The management team of Biocon Limited (BSE code: 532523, NSE Id: BIOCON) will organize a **conference call for Analysts and Investors on Friday, 10th November 2023 at 6:30 pm IST** following the announcement of financial results for the quarter ended September 30, 2023. The call will be conducted over Zoom.

Conference Call Details	
Date	Friday, 10 th November, 2023
Time	18:30 hrs - 20:00 hrs, IST
Registration Link	Click here
Recording	Will be made available within 24 hrs from the end of the call on the Company website (Biocon > Investors > Financial Information > Earnings Call Recordings)
Conference Call Transcript	Will be made available within 5 working days from the call date on the Company website (Biocon > Investors > Financial Information > Earnings Call Transcripts)

Note: Participants are requested to join 10 minutes in advance of the call start time.

For further information please contact:

Saurabh Paliwal

Investor Relations – Biocon Limited

P: +91 80 2808 2040/ +91 95383 80801

E: saurabh.paliwal@biocon.com

Safe Harbor: Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current assumptions and expectations concerning future developments and their potential effects upon Biocon and its subsidiaries/associates. There can be no assurance that future developments affecting Biocon and its subsidiaries/associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties that may cause actual results to differ, possibly materially, from those contemplated by such forward-looking statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither our Company, our directors, nor any of our subsidiaries/ associates assume any obligation to update or otherwise revise any statements reflecting circumstances arising after the conference call's conclusion to reflect the occurrence of underlying events, even if the underlying assumptions and expectations do not come to fruition.